颅内动脉狭窄程度指导下抗血小板治疗对AIS患者早期神经功能恶化的影响

李凤娥, 田祺, 成振华, 刘文运, 任璐, 张乃保

湖南师范大学学报医学版 ›› 2026, Vol. 23 ›› Issue (3) : 39-45.

PDF(2061 KB)
PDF(2061 KB)
湖南师范大学学报医学版 ›› 2026, Vol. 23 ›› Issue (3) : 39-45.
临床医学

颅内动脉狭窄程度指导下抗血小板治疗对AIS患者早期神经功能恶化的影响

  • 李凤娥1, 田祺2, 成振华3, 刘文运1, 任璐1, 张乃保1
作者信息 +

Effect of Antiplatelet Therapy Guided by Intracranial Artery Stenosis on Early Neurological Deterioration in Acute Ischemic Stroke Patients

  • LI Feng'e1, TIAN Qi2, CHENG Zhenhua3, LIU Wenyun1, REN Lu1, ZHANG Naibao1
Author information +
文章历史 +

摘要

目的 探讨不同程度颅内动脉狭窄的急性缺血性脑卒中(acute ischemic stroke,AIS)患者分别接受替罗非班与阿司匹林治疗的有效性与安全性差异。方法 回顾性纳入201例AIS患者,根据患者实际治疗方式分为对照组(口服阿司匹林肠溶片+硫酸氢氯吡格雷片,n=97)和观察组(静脉输注替罗非班注射液,然后口服阿司匹林肠溶片+硫酸氢氯吡格雷片,n=104)。进一步根据责任血管狭窄程度将两组患者分为无狭窄、轻度至中度狭窄、严重狭窄或动脉闭塞三个亚组。比较各组基线资料、治疗前后美国国立卫生院脑卒中(national institutes of health stroke scale,NIHSS)评分、早期神经功能恶化(early neurological deterioration,END)发生率、90 d预后良好率、血小板聚集率变化及出血与死亡事件发生情况。结果 各狭窄程度亚组内,两组基线资料具有可比性。治疗后,各亚组NIHSS评分及血小板聚集率均较治疗前显著降低(P<0.05),且观察组评分均显著低于对照组(P<0.05)。在严重狭窄或闭塞患者中,观察组END发生率显著低于对照组,90 d预后良好率显著高于对照组(P<0.05);而在无狭窄及轻中度狭窄患者中,两组END发生率及预后良好率差异均无统计学意义。安全性方面,各亚组内两组间全身性出血事件发生率及死亡率比较,差异均无统计学意义,且均未发生症状性颅内出血。结论 替罗非班对严重颅内动脉狭窄或闭塞的AIS患者具有显著疗效与安全性优势,对非严重狭窄患者则与阿司匹林相当。

Abstract

Objective To investigate the differences in efficacy and safety between tirofiban and aspirin in patients with acute ischemic stroke (AIS) and varying degrees of intracranial artery stenosis. Methods A total of 201 AIS patients were retrospectively enrolled and divided into a control group (oral aspirin enteric-coated tablets + clopidogrel bisulfate tablets, n=97) and an observation group (intravenous infusion of tirofiban injection, followed by oral aspirin enteric-coated tablets + clopidogrel bisulfate tablets, n=104) according to the actual treatment received. Patients in both groups were further stratified into three subgroups according to the severity of the culprit vessel stenosis: no stenosis, mild to moderate stenosis, and severe stenosis or arterial occlusion. Baseline characteristics, NIHSS scores before and after treatment, incidence of END, 90-day favorable prognosis rate, changes in platelet aggregation rate, and the occurrence of bleeding and death events were compared. Results Baseline characteristics were comparable between the two groups within each stenosis subgroup. After treatment, NIHSS scores and platelet aggregation rates significantly decreased in all subgroups compared to pre-treatment levels (P<0.05), and the scores in the observation group were significantly lower than those in the control group (P<0.05). In patients with severe stenosis or occlusion, the incidence of END was significantly lower and the 90-day favorable prognosis rate was significantly higher in the observation group compared to the control group (P<0.05). In contrast, no statistically significant differences were found in END incidence or favorable prognosis rate between the two groups for patients with no stenosis or mild to moderate stenosis. Regarding safety, there were no statistically significant differences in the incidence of systemic bleeding events or mortality between the two groups within any stenosis subgroup, and no symptomatic intracranial hemorrhage occurred in any group. Conclusion Tirofiban has significant efficacy and safety advantages in AIS patients with severe intracranial artery stenosis or occlusion, while its effects are comparable to aspirin in patients with non-severe stenosis.

关键词

颅内动脉狭窄 / 急性缺血性脑卒中 / 替罗非班 / 阿司匹林 / 早期神经功能恶化

Key words

intracranial artery stenosis / acute ischemic stroke / tirofiban / aspirin / early neurological deterioration

引用本文

导出引用
李凤娥, 田祺, 成振华, 刘文运, 任璐, 张乃保. 颅内动脉狭窄程度指导下抗血小板治疗对AIS患者早期神经功能恶化的影响[J]. 湖南师范大学学报医学版. 2026, 23(3): 39-45
LI Feng'e, TIAN Qi, CHENG Zhenhua, LIU Wenyun, REN Lu, ZHANG Naibao. Effect of Antiplatelet Therapy Guided by Intracranial Artery Stenosis on Early Neurological Deterioration in Acute Ischemic Stroke Patients[J]. Journal of Hunan Normal University(Medical Science). 2026, 23(3): 39-45
中图分类号: R743.3   

参考文献

[1] QUINN T, KITAGAWA K, LEUNG T, et al.A systematic literature review on the burden of disease for patients with moderate to severe acute ischemic stroke[J]. Medicine (Baltimore), 2025, 104(3): e41249.
[2] GOUTA N, DAOUSSI N, BEN DHIA R, et al.Early neurological deterioration in ischemic stroke: prevalence, predictors, causes and 90-day outcome in a retrospective Tunisian cohort[J]. Neurohospitalist, 2025, 15(4): 363-371.
[3] LI J, CHANG H, DU S, et al.Development and validation of a web-based machine learning model for predicting early neurological deterioration following stroke thrombolysis: multicenter study[J]. J Med Internet Res, 2025, 27: e77858.
[4] NAVARRO JC, PEDREGOSA BIC, PUNSALAN MTS, et al.Intracranial atherosclerotic stenosis in Asia: a systematic scoping and rapid review of prevalence, frequency in ischaemic stroke and risk factors[J]. BMJ Neurol Open, 2025, 7(2): e001164.
[5] YANG Y, MEI C, GUO X, et al.Interpretable machine learning for predicting early neurological deterioration in symptomatic intracranial atherosclerotic stenosis[J]. Front Neurol, 2025, 16: 1667119.
[6] ZHAO W, LI S, LI C, et al.Effects of tirofiban on neurological deterioration in patients with acute ischemic stroke: a randomized clinical trial[J]. JAMA Neurol, 2024, 81(6): 594-602.
[7] CHIMOWITZ MI, KOKKINOS J, STRONG J, et al.The warfarin-aspirin symptomatic intracranial disease study[J]. Neurology, 1995, 45(8): 1488-1493.
[8] 钟迪, 张舒婷, 吴波. 中国急性缺血性脑卒中诊治指南2018解读[J]. 中国现代神经疾病杂志, 2019, 19(11): 897-901.
[9] 康利高阁, 高颖, 唐欢, 等. 急性缺血性中风发病24 h内头颅CT相关特征与早期神经功能恶化、90 d预后、中医证候要素的相关性研究[J]. 北京中医药大学学报, 2025, 48(3): 424-437.
[10] 谭冉, 邓立普. 急性缺血性脑卒中损伤机制及其治疗药物研究新进展[J]. 医学食疗与健康, 2021, 19(18): 206-208.
[11] LIU Q, LU X, YANG H, et al.Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy: Systematic review and meta-analysis[J]. Clin Neurol Neurosurg, 2022, 222: 107449.
[12] WANG M, ZHANG F, GUO Q, et al.Efficacy, safety, and effect on platelet activation of the timing of administration of tirofiban in patients with acute ischemic stroke[J]. Am J Transl Res, 2025, 17(2): 791-805.
[13] LIU Y, XU X, ZHOU Y, et al.Nomogram for predicting the occurrence of progressive ischemic stroke: a single-center retrospective study[J]. Eur J Med Res, 2025, 30(1): 880.
[14] SVEDUNG WETTERVIK T, FAHLSTRÖM M, WIKSTRÖM J, et al. Cerebrovascular reserve in moyamoya disease: relation to cerebral blood flow, capillary dysfunction, oxygenation, and energy metabolism[J]. Front Neurol, 2023, 14: 1190309.
[15] GUO L, ZHANG J, LV K, et al.Multimodal monitoring of cerebral perfusion in carotid endarterectomy patients: a computational fluid dynamics study[J]. Front Neurol, 2024, 15: 1455401.
[16] 韩志莹, 吴海华. 血小板聚集率联合D-二聚体对急性缺血性卒中患者静脉溶栓后早期神经功能恶化的预测研究[J]. 临床血液学杂志, 2025, 38(8): 593-597.
[17] 李晓慧, 李晓民, 魏明阳, 等. 替罗非班用于急性缺血性脑卒中早期神经功能恶化的疗效分析[J]. 中国药房, 2025, 36(10): 1221-1225.
[18] JIANG Y, HUANG W, ZHANG Y, et al.Tirofiban in acute ischemic stroke: mechanistic rationale, clinical advances, and emerging therapeutic strategies[J]. Drugs, 2025, 85(10): 1269-1287.
[19] YANG Q, HE Q, MAO X, et al.Evaluation of safety and efficacy of tirofiban injection for treating acute ischemic stroke beyond standard time window[J]. Sci Rep, 2025, 15(1): 27399.

基金

吕梁市科技计划项目“替罗非班通过 PPARγ调控 CD40/CD40L 通路治疗急性缺血性卒中的机制研究”(2023SHFZ07)

PDF(2061 KB)

Accesses

Citation

Detail

段落导航
相关文章

/

〈 〉